[
  {
    "ts": "2026-02-18T02:21:20+00:00",
    "headline": "This State Has More Millionaires Per Capita Than Any Other",
    "summary": "There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That’s a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America’s 50 states have more millionaires than others. By the process ... This State Has More Millionaires Per Capita Than Any Other",
    "url": "https://247wallst.com/investing/2026/02/17/this-state-has-more-millionaires-per-capita-than-any-other/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c78046f0-1ca5-32dc-85cf-6f8c38a5db54",
      "content": {
        "id": "c78046f0-1ca5-32dc-85cf-6f8c38a5db54",
        "contentType": "STORY",
        "title": "This State Has More Millionaires Per Capita Than Any Other",
        "description": "",
        "summary": "There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That’s a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America’s 50 states have more millionaires than others. By the process ... This State Has More Millionaires Per Capita Than Any Other",
        "pubDate": "2026-02-18T02:21:20Z",
        "displayTime": "2026-02-18T02:21:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/f7109cc114790579cb27b509e454b2fa",
          "originalWidth": 2560,
          "originalHeight": 1707,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BsdaEb1kKl4fYOmiuFHAbQ--~B/aD0xNzA3O3c9MjU2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/24_7_wall_st__718/f7109cc114790579cb27b509e454b2fa.cf.webp",
              "width": 2560,
              "height": 1707,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.yBu0G0aPHwBbKcaFQSnrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/f7109cc114790579cb27b509e454b2fa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/17/this-state-has-more-millionaires-per-capita-than-any-other/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/state-more-millionaires-per-capita-022120447.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T10:32:55+00:00",
    "headline": "XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500",
    "summary": "Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of market conditions. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers concentrated exposure to this defensive sector, but with concentration comes tradeoffs investors must understand before allocating capital. Pure Healthcare Exposure With Mega-Cap Anchors XLV functions ... XLV is A $41 Billion Defensive Healthcare Play That Looks",
    "url": "https://247wallst.com/investing/2026/02/18/xlv-is-a-41-billion-defensive-healthcare-play-that-looks-good-until-you-compare-to-the-sp-500/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "86e0edc5-c207-39dd-aaba-6769f2d97f86",
      "content": {
        "id": "86e0edc5-c207-39dd-aaba-6769f2d97f86",
        "contentType": "STORY",
        "title": "XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500",
        "description": "",
        "summary": "Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of market conditions. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers concentrated exposure to this defensive sector, but with concentration comes tradeoffs investors must understand before allocating capital. Pure Healthcare Exposure With Mega-Cap Anchors XLV functions ... XLV is A $41 Billion Defensive Healthcare Play That Looks",
        "pubDate": "2026-02-18T10:32:55Z",
        "displayTime": "2026-02-18T10:32:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/f4e0726dddf55916b1b34f9dcc2d4446",
          "originalWidth": 1366,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IgC6HfL8FtUwNbKCRAjPOQ--~B/aD03Njg7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/f4e0726dddf55916b1b34f9dcc2d4446.cf.webp",
              "width": 1366,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kXpSTrapkjD7wcFAONghGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/f4e0726dddf55916b1b34f9dcc2d4446.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/18/xlv-is-a-41-billion-defensive-healthcare-play-that-looks-good-until-you-compare-to-the-sp-500/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/xlv-41-billion-defensive-healthcare-103255420.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "UNH"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T12:09:13+00:00",
    "headline": "Is Kenvue (KVUE) Attractively Priced After Spin Off From Johnson & Johnson?",
    "summary": "If you are wondering whether Kenvue's current share price lines up with its underlying value, you are not alone, this article breaks down what the market might be pricing in. The stock last closed at US$18.41, with returns of 0.5% over 7 days, 7.0% over 30 days, 6.3% year to date and a 12.7% decline over the past year, which gives a mixed picture of recent sentiment. Recent headlines have focused on Kenvue's position as a standalone consumer health company following its separation from...",
    "url": "https://finance.yahoo.com/news/kenvue-kvue-attractively-priced-spin-120913087.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "84af5041-761b-373a-88f4-cd1a6963514f",
      "content": {
        "id": "84af5041-761b-373a-88f4-cd1a6963514f",
        "contentType": "STORY",
        "title": "Is Kenvue (KVUE) Attractively Priced After Spin Off From Johnson & Johnson?",
        "description": "",
        "summary": "If you are wondering whether Kenvue's current share price lines up with its underlying value, you are not alone, this article breaks down what the market might be pricing in. The stock last closed at US$18.41, with returns of 0.5% over 7 days, 7.0% over 30 days, 6.3% year to date and a 12.7% decline over the past year, which gives a mixed picture of recent sentiment. Recent headlines have focused on Kenvue's position as a standalone consumer health company following its separation from...",
        "pubDate": "2026-02-18T12:09:13Z",
        "displayTime": "2026-02-18T12:09:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d690536de0c7b23c26cf14ed9066767e",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W2Y4xgPz6k2sJssKwLaiuQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d690536de0c7b23c26cf14ed9066767e.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XxQ2W.u4ql9pr6kIHenw7g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d690536de0c7b23c26cf14ed9066767e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kenvue-kvue-attractively-priced-spin-120913087.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kenvue-kvue-attractively-priced-spin-120913087.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T15:21:45+00:00",
    "headline": "J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push",
    "summary": "Feb 18 (Reuters) - Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale",
    "url": "https://finance.yahoo.com/news/j-j-invest-1-billion-152145560.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "5178d860-ca8d-31f4-9802-9328a5504996",
      "content": {
        "id": "5178d860-ca8d-31f4-9802-9328a5504996",
        "contentType": "STORY",
        "title": "J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push",
        "description": "",
        "summary": "Feb 18 (Reuters) - Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale",
        "pubDate": "2026-02-18T15:21:45Z",
        "displayTime": "2026-02-18T15:21:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/7d28972b448cced4f4cefed8732e1f0f",
          "originalWidth": 800,
          "originalHeight": 571,
          "caption": "A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023.  REUTERS/Brendan McDermid",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PbUe6vH2FHz0.60wTkOl8g--~B/aD01NzE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/7d28972b448cced4f4cefed8732e1f0f.cf.webp",
              "width": 800,
              "height": 571,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KJkB67QvnWtzG2Sy_CtaKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/7d28972b448cced4f4cefed8732e1f0f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-invest-1-billion-152145560.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-invest-1-billion-152145560.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T15:15:00+00:00",
    "headline": "Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania",
    "summary": "NEW BRUNSWICK, N.J., February 18, 2026--Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neuro",
    "url": "https://finance.yahoo.com/news/johnson-johnson-expands-u-footprint-151500564.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "3c1d7dc4-0d45-318b-a77a-8e0b1a72d832",
      "content": {
        "id": "3c1d7dc4-0d45-318b-a77a-8e0b1a72d832",
        "contentType": "STORY",
        "title": "Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania",
        "description": "",
        "summary": "NEW BRUNSWICK, N.J., February 18, 2026--Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neuro",
        "pubDate": "2026-02-18T15:15:00Z",
        "displayTime": "2026-02-18T15:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/6fa1e10c5005552f88305f40004d3144",
          "originalWidth": 480,
          "originalHeight": 268,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fwkB.zTVrrFEfAHXHs42tA--~B/aD0yNjg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6fa1e10c5005552f88305f40004d3144.cf.webp",
              "width": 480,
              "height": 268,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/haAVtpEgMFZvQNuCsUFERQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6fa1e10c5005552f88305f40004d3144.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-expands-u-footprint-151500564.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-expands-u-footprint-151500564.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T14:15:55+00:00",
    "headline": "Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?",
    "summary": "Verizon (NYSE: VZ) and Johnson & Johnson (NYSE: JNJ) both rewarded shareholders with dividend increases this quarter, but their paths to sustaining those payouts look very different. Verizon raised its quarterly dividend to $0.69 per share, marking its 19th consecutive annual raise. Johnson & Johnson lifted its quarterly payout to $1.30 per share, extending a ... Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?",
    "url": "https://247wallst.com/investing/2026/02/18/verizon-vs-johnson-johnson-which-dividend-hike-winner-is-the-better-buy/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "debb3fd0-b57f-3aa2-b395-e324418d31b8",
      "content": {
        "id": "debb3fd0-b57f-3aa2-b395-e324418d31b8",
        "contentType": "STORY",
        "title": "Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?",
        "description": "",
        "summary": "Verizon (NYSE: VZ) and Johnson & Johnson (NYSE: JNJ) both rewarded shareholders with dividend increases this quarter, but their paths to sustaining those payouts look very different. Verizon raised its quarterly dividend to $0.69 per share, marking its 19th consecutive annual raise. Johnson & Johnson lifted its quarterly payout to $1.30 per share, extending a ... Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?",
        "pubDate": "2026-02-18T14:15:55Z",
        "displayTime": "2026-02-18T14:15:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/a14e8a901cf705219b59ed35accb6fda",
          "originalWidth": 1500,
          "originalHeight": 1000,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZIeSnG4.PsPPWBSge3pyQ--~B/aD0xMDAwO3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/24_7_wall_st__718/a14e8a901cf705219b59ed35accb6fda.cf.webp",
              "width": 1500,
              "height": 1000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8AnBTv2F2cRo0XapLEkpCA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/a14e8a901cf705219b59ed35accb6fda.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/18/verizon-vs-johnson-johnson-which-dividend-hike-winner-is-the-better-buy/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/verizon-vs-johnson-johnson-dividend-141555536.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VZ"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T15:44:00+00:00",
    "headline": "Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory",
    "summary": "The facility is part of the company’s plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.",
    "url": "https://www.wsj.com/health/pharma/johnson-johnson-to-invest-more-than-1-billion-in-pennsylvania-cell-therapy-factory-ad19b30e?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "662c87de-d00c-3452-bf1a-cc5c3da46211",
      "content": {
        "id": "662c87de-d00c-3452-bf1a-cc5c3da46211",
        "contentType": "STORY",
        "title": "Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory",
        "description": "",
        "summary": "The facility is part of the company’s plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.",
        "pubDate": "2026-02-18T15:44:00Z",
        "displayTime": "2026-02-18T15:44:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/662c87de-d00c-3452-bf1a-cc5c3da46211/johnson-johnson-to-invest.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/97ed8c271156784503e0035c2194c12b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n.kkXzIuw6Jo1sp9pxW6Vw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/97ed8c271156784503e0035c2194c12b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5kj1adYkx4VJGW9m7tIuNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/97ed8c271156784503e0035c2194c12b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/johnson-johnson-to-invest-more-than-1-billion-in-pennsylvania-cell-therapy-factory-ad19b30e?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T14:00:06+00:00",
    "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-trending-stock-140006973.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1f6f3baa-fdb9-32f1-9997-55bb124ba675",
      "content": {
        "id": "1f6f3baa-fdb9-32f1-9997-55bb124ba675",
        "contentType": "STORY",
        "title": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
        "description": "",
        "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
        "pubDate": "2026-02-18T14:00:06Z",
        "displayTime": "2026-02-18T14:00:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83",
          "originalWidth": 900,
          "originalHeight": 633,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y5JgUaFZFuBLe5dh5H4ng--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83.cf.webp",
              "width": 900,
              "height": 633,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IGtpvtZ0OkzJMDD0I3exBg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-trending-stock-140006973.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-trending-stock-140006973.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T16:17:00+00:00",
    "headline": "Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues",
    "summary": "HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.",
    "url": "https://finance.yahoo.com/news/halozymes-q4-earnings-miss-higher-161700677.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6095e5af-dbf2-3866-b018-b27d50d417d4",
      "content": {
        "id": "6095e5af-dbf2-3866-b018-b27d50d417d4",
        "contentType": "STORY",
        "title": "Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues",
        "description": "",
        "summary": "HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.",
        "pubDate": "2026-02-18T16:17:00Z",
        "displayTime": "2026-02-18T16:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/57.Lfvcoa8N_9pHFAUTShA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/39hBnd4FwGlouiqapgQKxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/halozymes-q4-earnings-miss-higher-161700677.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/halozymes-q4-earnings-miss-higher-161700677.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]